Inari Medical, Inc. (NASDAQ:NARI) Shares Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC boosted its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 99.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,621 shares of the company’s stock after acquiring an additional 22,780 shares during the quarter. Knights of Columbus Asset Advisors LLC owned about 0.08% of Inari Medical worth $2,962,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust acquired a new stake in Inari Medical during the 1st quarter worth approximately $25,000. Quarry LP acquired a new stake in Inari Medical during the 2nd quarter worth approximately $27,000. Fifth Third Bancorp lifted its position in Inari Medical by 54.3% during the 3rd quarter. Fifth Third Bancorp now owns 486 shares of the company’s stock worth $32,000 after acquiring an additional 171 shares during the period. Point72 Middle East FZE acquired a new stake in Inari Medical during the 4th quarter worth approximately $55,000. Finally, FMR LLC lifted its position in Inari Medical by 42.6% during the 2nd quarter. FMR LLC now owns 824 shares of the company’s stock worth $56,000 after acquiring an additional 246 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $41.13, for a total transaction of $1,645,200.00. Following the sale, the director now owns 1,003,296 shares in the company, valued at $41,265,564.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $41.13, for a total transaction of $1,645,200.00. Following the sale, the director now owns 1,003,296 shares in the company, valued at $41,265,564.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mitch C. Hill sold 6,000 shares of the firm’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $40.96, for a total value of $245,760.00. Following the sale, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,451 shares of company stock worth $1,949,000. 10.60% of the stock is owned by insiders.

Inari Medical Trading Down 0.1 %

Shares of NASDAQ:NARI opened at $38.59 on Friday. The business’s fifty day moving average price is $46.89 and its two-hundred day moving average price is $55.25. Inari Medical, Inc. has a one year low of $37.92 and a one year high of $71.85.

Inari Medical (NASDAQ:NARI) last announced its earnings results on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). The company had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. Inari Medical’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.11) EPS. As a group, sell-side analysts expect that Inari Medical, Inc. will post -0.39 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and set a $75.00 target price on shares of Inari Medical in a research note on Friday, April 12th. Piper Sandler downgraded Inari Medical from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $85.00 to $55.00 in a research note on Thursday, February 29th. Truist Financial cut their target price on Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research note on Friday, March 22nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $72.00 target price on shares of Inari Medical in a research note on Wednesday, March 6th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $73.71.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.